Skip to Navigation Skip to Search Skip to Content
Search All Centers

Multiple Myeloma Roundtable: Immunotherapies & MRD Debate

Published on December 16, 2020

Experts Discuss the Latest Developments in Multiple Myeloma Research

Each year during the American Society of Hematology (ASH) Annual Meeting & Exposition, Patient Power brings together several of the world’s leading experts in multiple myeloma for a roundtable discussion of the latest myeloma research and news. Keep watching to hear three renowned experts and Patient Power co-founder Andrew Schorr discuss the state of multiple myeloma treatment today including advances in immunotherapy, new promising drug options, the role of minimal residual disease (MRD) testing in determining treatment paths, and other important topics including disparities in multiple myeloma care.

Joining us for this segment are Dr. James Berenson, MD, Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, Dr. Robert Orlowski, MD, PhD, Director of the Myeloma Section at MD Anderson Cancer Center and Dr. Rafael Fonseca, MD, Myeloma Doctor and Interim Executive Director at the Mayo Clinic Cancer Center

This program is sponsored by GlaxoSmithKline. This organization has no editorial control. It is produced by Patient Power, and Patient Power is solely responsible for program content.


Recommended for You:

Featuring